Monthly Prescribing Reference

Scemblix Gets Accelerated Approval for Newly Diagnosed Ph+ CML in Chronic Phase

The major molecular response rate was 68% with asciminib and 49% with IS-TKIs (difference, 19% [95% CI, 10-28]; P .001). The Food and Drug Administration (FDA) has granted accelerated approval to ...
Nasdaq

Novartis' Scemblix Receives Accelerated FDA Approval For Newly Diagnosed Ph+ CML In Adults

(RTTNews) - Novartis (NVS) announced that Scemblix (asciminib) was granted accelerated approval by the US Food and Drug Administration for adult patients with newly diagnosed Philadelphia ...
Science Daily

Triplet regimen yields promising response in advanced-phase chronic myeloid leukemia

According to new research, 80% of patients with previously untreated or relapsed/refractory advanced-phase chronic myeloid leukemia (CML) -- including both accelerated or myeloid blast phases of the ...
Healio

FDA grants accelerated approval to asciminib for chronic myeloid leukemia

Please provide your email address to receive an email when new articles are posted on . The FDA granted accelerated approval to asciminib for the treatment of adults with newly diagnosed Philadelphia ...

Alembic Pharmaceuticals receives USFDA tentative approval for Bosutinib Tablets, 400 mg

Alembic Pharmaceuticals has received tentative approval from the US Food & Drug Administration (USFDA) for its supplemental Abbreviated New Drug Application (sANDA) Bosutinib Tablets, 400 mg. The ...